K-Dur: profile and news
FTC chief concerned about drug patent deals Jan 11, 2006
The FTC had issued a finding that the settlement illegally kept cheaper versions of Schering-Plough's blood pressure drug K-Dur off the market. ... - Reuters
Andrx Corporation Reports 2005 Third Quarter Results Nov 8, 2005
The decrease is primarily due to decreases from our generic versions of Glucotrol XL(R), supplied by Pfizer, OTC Claritin-D(R) 24, K-Dur(R) and Glucophage(R ... - PharmaLive.com (press release),
US top court seeks advice on FTC case vs. Schering 31 Oct 2005
Trade Commission's case against Schering-Plough, which accuses the company of illegally keeping cheaper versions of its blood pressure drug K-Dur off the market ... - Reuters
UPDATE 1-US FTC takes Schering patent case to high court Aug 30, 2005
Circuit Court, which rejected an earlier finding by the FTC that Schering-Plough had illegally kept cheaper versions of its blood pressure drug K-Dur off the ... - Reuters
Justices petitioned in Schering dispute Aug 31, 2005
...have the Supreme Court hear its arguments that the Kenilworth-based pharmaceutical company delayed generic competition to its potassium drug K-Dur 20 through ... - NorthJersey.com,
Commentary: Ruling helps drugmakers, hurts public Aug 27, 2005
The case involves a major drug company, Schering-Plough Corp., and K-Dur, a drug the company developed to treat patients with low potassium. ... - Providence Journal (subscription),
Antitrust: FTC confronts decision that liberally allows patent ... Apr 26, 2005
...of Appeals set aside an FTC order that barred Schering-Plough from settling an infringement suit with generic makers over the patented blood pressure drug K-Dur ... - Patently-O
Business briefs Apr 23, 2005
Trade Commission said Friday it filed a petition for the full 11th Circuit Court in Atlanta to rehear a case involving Schering-Plough's K-Dur 20 potassium ... - NorthJersey.com
Schering-Plough Reports Financial Results for 2005 First Quarter Apr 21, 2005
Plough did not violate antitrust laws in patent litigation settlements involving its controlled-release potassium chloride supplement K-DUR 20 (potassium ... - PR Newswire
FTC Staff Requests Re-Hearing in Schering-Plough Case Apr 22, 2005
04-10688, and re-hear the case en banc. K-Dur 20 potassium chloride supplement off the US market. AHP settled with the Commission in April 2002. ... - I-Newswire.com
Schering-Plough wins round in battle over K-Dur 20 deals Mar 10, 2005
Circuit in Atlanta vacated an FTC opinion that found the Kenilworth-based company made illegal agreements with competitors to delay generic versions of K-Dur 20 ... - NorthJersey.com,
Schering-Plough pleased with ruling Mar 9, 2005
...that Schering-Plough did not violate antitrust laws in patent litigation settlements involving its controlled-release potassium chloride supplement K-DUR 20. ... - BusinessWeek
Court Overturns FTC in Schering Case Mar 9, 2005
...(SGP), rejecting a finding by US antitrust enforcers that the company illegally kept cheaper versions of blood pressure drug K-Dur off the market. ... - MSN Money
Court Overturns FTC in Schering Case Mar 9, 2005
Quote, Profile, Research) , rejecting a finding by US antitrust enforcers that the company illegally kept cheaper versions of blood pressure drug K-Dur off the ... - Reuters
Schering-Plough gets favorable ruling Mar 9, 2005
Wednesday that a federal appellate court ruled Tuesday that it had not violated antitrust laws in patent litigation settlements involving K-DUR 20its controlled ... - MarketWatch
Public company news Mar 13, 2005
The FTC found in 2003 that Schering-Plough unlawfully paid Upsher-Smith $60 million to keep low-cost alternatives to Schering-Plough's K-Dur 20 potassium ... - Pioneer Press,
Court Rejects FTC Decision, Backs Schering Mar 10, 2005
Corp., rejecting a finding by US antitrust enforcers that the company illegally kept less expensive versions of the high blood pressure drug K-Dur off the ... - Los Angeles Times (subscription),
Payment from a Patentee to a Generic Manufacturer Does Not Create ... Mar 10, 2005
...of Appeals set aside an FTC order that barred Schering-Plough from settling an infringement suit with generic makers over the patented blood pressure drug K-Dur ... - Patently-O,
Highlights of rising and falling US stocks Mar 10, 2005
Schering-Plough Corp. (SGP) said a federal appellate court ruled it didn't violate antitrust laws in patent litigation settlements involving K-DUR 20. ... - Investor's Business Daily (subscription)
US: Court Overturns FTC in Schering Case Mar 9, 2005
The K-Dur case is one of a string of FTC investigations that focus on drug patent settlements and whether they stifle generic competition. - Keralanext,
